PULSE
Live / Applied — Non-final action written — not yet mailed (as of 27 Mar 2026)
What this means for you
Not registered yet, but its 21 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79437917
- Mark type
- Design + words
- Filed
- 21 Oct 2025
Goods and services
- Class 040 — Treatment of materials: Custom manufacturing of cell culture and cell therapy and gene edited cell therapy apparatus and equipment for others; custom manufacture of medicines; custom manufacture of biopharmaceuticals, namely, therapeutic cells, laboratory-modified cells, and gene edited cells to prevent or treat conditions or diseases that can be transferred into the body, for others; information, advice and consultancy in relation to all the aforesaid.
- Class 042 — Scientific and technological services: Platform-as-a-service [PaaS] in the field of cell therapy, and cell therapy development; providing temporary use of a a web-based platform that offers tools, technologies, processes and data analysis capabilities for researchers and scientists to streamline the development and characterization of cell lines; providing temporary use of a technological platform for the manufacturing of cell-based therapies, including technology, processes, and data analytics capabilities for process optimization and quality control; platform-as-a-service [PaaS] for monitoring patient health; laboratory research in the field of biotechnology; scientific research, design and technological development services in biotechnology, the pharmaceutical and medical industry; scientific research, design and development of scientific cell culture, cell therapy or gene edited cell therapy equipment and apparatus; scientific research, design and development of cell culture, cell therapy or gene edited cell therapy manufacturing equipment, manufacturing systems and manufacturing processes for others; scientific consultation services in the field of biotechnology, specifically in relation to cell culture, cell therapy, or gene edited cell therapy manufacturing; providing information with respect to scientific research in the field of stem cells, cell therapy and edited cell gene therapy; initial set-up, configuration, and calibration, of scientific apparatus, machines and equipment used for cell culture, cell therapy and edited cell gene therapy; industrial biotechnology statistical analysis to extract insights from cell line development experiments and data; research and development in the field of cells, therapeutic cells, cell therapies, cellular therapies and gene edited cell therapies; culturing of cells for scientific research purposes.
Owner
Prosecution history
- 28 Mar 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 27 Mar 2026 — NON-FINAL ACTION WRITTEN
- 06 Mar 2026 — ASSIGNED TO EXAMINER
- 02 Dec 2025 — APPLICATION FILING RECEIPT MAILED
- 02 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Nov 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB